HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Asenapine in clinical practice: preliminary results from a naturalistic observational study.

AbstractOBJECTIVE:
Asenapine, a second-generation antipsychotic, seems to be an effective and tolerable alternative to other treatments for patients with manic or mixed episodes. The objective of our naturalistic observational study was to identify asenapine responders and remitters and to compare responders vs. non-responders and remitters vs. non-remitters, as far as clinical and socio-demographic features are concerned.
MATERIALS AND METHODS:
We recruited patients with diagnosis of manic episode in bipolar I (BD I) or schizoaffective disorder, with clinical indication to asenapine treatment. Patients’ assessment was performed at baseline (T0), after 1 week (T1) and after 4 weeks (T2) of treatment, with the Young Mania Rating Scale (YMRS; T0,T1,T2) and Hamilton Rating Scale for Depression (HAM-D; T0, T2). According to YMRS scores, we classified patients as early improvers, treatment responders, and treatment remitters.
RESULTS:
A significant decrease was found in HAM-D scores from baseline to T2, with no significant difference between remitters and non-remitters or responders vs. non-responders.The YMRS score significantly improved from baseline to T2, with a significant difference between remitters and non-remitters, but not between responders and non-responders. No difference was found between responders and non-responders as far as socio-demographic and clinical variables, and questionnaire baseline scores are concerned. Remitters and non-remitters showed significant differences in baseline YMRS scores, which were lower in the first and in the type of current episode, which was more frequently moderate in the former than in the latter.
CONCLUSIONS:
Early improvers comprised 51% of subjects, responders comprised 91.9% and remitters comprised 59.4%. Elderly manic patients with neurological impairment and/or dementia may have poorer therapeutic outcomes. Our results suggest that: 1) decision regarding treatment discontinuation should be cautious in patients who fail to have an early response to asenapine; 2) different diagnosis (BDor schizoaffective disorder) does not seem to have a significant impact on asenapine efficacy; 3) remission with asenapine is more likely to happen for less severe manic episodes. Further naturalistic studies on larger samples are required to support our findings.
AuthorsCarla Gramaglia, Maria Cristina Rizza, Eleonora Gattoni, Eleonora Gambaro, Sarah Di Marco, Isabella Coppola, Annalisa Rossi, Amalia Jona, Fredrica Imperatori, Pierluigi Prosperini, Nunzia Chieppa, Valeria Binda, Serena Farruggio, Elena Grossini, Patrizia Zeppegno
JournalRivista di psichiatria (Riv Psichiatr) 2014 Nov-Dec Vol. 49 Issue 6 Pg. 241-6 ISSN: 2038-2502 [Electronic] Italy
PMID25668625 (Publication Type: Comparative Study, Journal Article, Observational Study)
Chemical References
  • Antipsychotic Agents
  • Dibenzocycloheptenes
  • Heterocyclic Compounds, 4 or More Rings
  • asenapine
Topics
  • Adult
  • Antipsychotic Agents (therapeutic use)
  • Bipolar Disorder (diagnosis, drug therapy)
  • Dibenzocycloheptenes
  • Female
  • Heterocyclic Compounds, 4 or More Rings (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Psychotic Disorders (diagnosis, drug therapy)
  • Surveys and Questionnaires
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: